Spielman v. Genzyme Corporation

CourtCourt of Appeals for the First Circuit
DecidedJune 1, 2001
Docket00-1775
StatusPublished

This text of Spielman v. Genzyme Corporation (Spielman v. Genzyme Corporation) is published on Counsel Stack Legal Research, covering Court of Appeals for the First Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Spielman v. Genzyme Corporation, (1st Cir. 2001).

Opinion

United States Court of Appeals For the First Circuit

No. 00-1775

MICHAEL SPIELMAN,

Plaintiff, Appellant,

v.

GENZYME CORP. and GENZYME DEVELOPMENT CORP.,

Defendants, Appellees.

APPEAL FROM THE UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF MASSACHUSETTS

[Hon. Edward F. Harrington, U.S. District Judge]

Before

Boudin, Lynch, and Lipez, Circuit Judges.

John Peter Zavez, with whom Adkins, Kelson & Zavez, P.C. were on brief, for appellant. Michael T. Gass, with whom Paige Scott Reed and Palmer & Dodge LLP were on brief, for appellees.

May 24, 2001 LIPEZ, Circuit Judge. Michael Spielman, the named plaintiff

in a putative class action, appeals the district court's dismissal of

his suit for lack of subject matter jurisdiction. The court found that

the plaintiff's individual damages claim failed to satisfy the amount-

in-controversy minimum set by 28 U.S.C. § 1332 for entry into federal

court. The court also rejected the plaintiff's alternative argument

that his claim for attorney's fees under Chapter 93A of the

Massachusetts Consumer Protection Statute fulfilled the amount-in-

controversy requirement because Massachusetts law allowed him to

aggregate all of the fees anticipated by the class. We agree that

Spielman does not meet the amount-in-controversy minimum and affirm the

district court's dismissal of his suit.

I.

In 1987, Michael Spielman, a New York resident, bought a

limited partnership interest in Genzyme Clinical Partners, L.P. (GCP),

which sought to develop a treatment for Gaucher's disease. At that

time Genzyme Development Corporation (Genzyme Development), a

subsidiary of Genzyme Corporation (Genzyme), was the general partner

of GCP. As general partner, Genzyme Development was obligated by law

and by the limited partnership agreement to issue annual federal and

state tax schedules to the limited partners. No schedules were issued

between 1987 and 1990. In 1990, the GCP limited partners approved the

-2- sale of the partnership's assets to Genzyme in exchange for shares of

common stock. As a result, GCP was liquidated.

This transaction had tax implications for Spielman and some

of the other 190 GCP limited partners who lived outside of

Massachusetts. Sometime after Genzyme bought GCP, the Massachusetts

Department of Revenue determined that the sale and liquidation was a

taxable event under state law. In 1993, the Department notified the

former limited partners who had not filed 1990 Massachusetts tax

returns that they owed state taxes on their share of the liquidation

income. Spielman was assessed a tax of $10,820, which he did not pay.

In 1995, the Department penalized Spielman for delinquent payment by

doubling the amount he owed to $21,640.

On November 9, 1995, Spielman filed a class action in

federal court on behalf of himself and similarly situated former GCP

limited partners against Genzyme Development and Genzyme.1 The

complaint included claims of negligent misrepresentation, common law

fraud, breach of fiduciary duty, and breach of contract. It alleged

that Genzyme Development's failure to issue the required 1990 tax

schedules for GCP caused Spielman and the other class members to incur

Massachusetts tax liability. As a resident of New York suing a

Massachusetts corporation, Spielman asserted diversity jurisdiction

1Genzyme Development ceased to exist in 1990, and Genzyme, as parent corporation, assumed its liability. Spielman's suit named both entities but proceeded against Genzyme alone.

-3- under 28 U.S.C. § 1332, but did not specify a damages amount. At the

time the suit was filed, § 1332(a) required that the "matter in

controversy" exceed $50,000 for federal court jurisdiction to attach.

See Act of Oct. 19, 1996, Pub. L. No. 104-317, 110 Stat. 3850 (amending

28 U.S.C. § 1332(a) so as to raise jurisdictional amount from $50,000

to $75,000).

Five days after filing the class action complaint, Spielman

filed an appeal with the Massachusetts Appellate Tax Board to determine

the taxes and penalty he owed for the GCP liquidation. On October 24,

1996, Genzyme filed a motion to dismiss for lack of subject matter

jurisdiction, alleging that Spielman's damages fell below the required

$50,000 minimum. In opposition to this motion, Spielman filed an

affidavit on November 21, 1996 claiming $21,640 in "double taxes,"

$16,211.47 in interest, $11,246.48 in penalties, and $1,305 in

accountant fees. The itemized damages totaled $50,402.95. The

affidavit asserted, however, that Spielman's damages as of the date his

complaint was filed were $61,673.77, though it did not explain the

$11,270.82 discrepancy between that amount and the itemized total.

On December 12, 1996, the district court denied Genzyme's

motion to dismiss for lack of subject matter jurisdiction, but stayed

Spielman's action pending the state Tax Board's ruling on the amount

of his tax liability. The court said: "This action . . . has been

prematurely brought. After a review of the papers and pleadings, it

-4- is not possible at this time to determine plaintiff's damages, as

damages can be reasonably calculated only upon completion of the state

administrative proceedings."

This stay remained in place for more than two years. Then

at a February 8, 1999 status conference, Spielman told the court that

the Tax Board had assessed his final tax liability at $10,820--the

taxes he owed for GCP's liquidation, with no assessment of penalties

or interest. Spielman also said that to achieve this result he had

paid attorney's fees of $7,000 and accountant's fees of $1,305, for a

total of $8,305. Spielman told the court he would consider whether the

Tax Board's ruling meant that he could no longer meet the amount-in-

controversy minimum. The next day, the court lifted the stay on

Spielman's class action.

Five months later, on July 16, 1999, Spielman asked the

court for leave to file an amended complaint. The amendment alleged

no new facts, but added a claim under Chapter 93A of the Massachusetts

Consumer Protection Act, which permits prevailing plaintiffs to recover

attorney's fees as part of their damages award. Genzyme protested,

arguing that Spielman's attempt to amend the complaint was untimely and

a "transparent attempt to establish federal court jurisdiction where

none exists." On September 22, 1999, the court granted Spielman's

request to amend the complaint, saying that the court's December 1996

stay accounted for the delayed filing of the amendment.

-5- On November 2, 1999, Genzyme renewed its motion to dismiss

for lack of subject matter jurisdiction, claiming that the state Tax

Board ruling established that Spielman had incurred at most $8,305 in

damages.2 In opposition to this motion, Spielman argued that his

damages claim for attorney's fees under Chapter 93A should include the

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Saint Paul Mercury Indemnity Co. v. Red Cab Co.
303 U.S. 283 (Supreme Court, 1938)
Snyder v. Harris
394 U.S. 332 (Supreme Court, 1969)
Zahn v. International Paper Co.
414 U.S. 291 (Supreme Court, 1973)
Barrett v. Veritas Offshore
239 F.3d 23 (First Circuit, 2001)
Vicente Acevedo Velez v. Crown Life Insurance Co.
599 F.2d 471 (First Circuit, 1979)
Quebe v. Ford Motor Co.
908 F. Supp. 446 (W.D. Texas, 1995)
Gilman v. Wheat, First Securities, Inc.
896 F. Supp. 507 (D. Maryland, 1995)
Visintine v. Saab Auto. AB
891 F. Supp. 496 (E.D. Missouri, 1995)
Ratliff v. Sears, Roebuck and Co.
911 F. Supp. 177 (E.D. North Carolina, 1995)
Coggins v. New England Patriots Football Club, Inc.
492 N.E.2d 1112 (Massachusetts Supreme Judicial Court, 1986)
Coggins v. New England Patriots Football Club, Inc.
550 N.E.2d 141 (Massachusetts Supreme Judicial Court, 1990)
Davis v. Bay State League
33 N.E. 591 (Massachusetts Supreme Judicial Court, 1893)
Boynton v. Tarbell
172 N.E. 340 (Massachusetts Supreme Judicial Court, 1930)
Commissioner of Insurance v. Massachusetts Accident Co.
61 N.E.2d 137 (Massachusetts Supreme Judicial Court, 1945)

Cite This Page — Counsel Stack

Bluebook (online)
Spielman v. Genzyme Corporation, Counsel Stack Legal Research, https://law.counselstack.com/opinion/spielman-v-genzyme-corporation-ca1-2001.